Biodefense has been advancing, particularly in the U.S., subsequent to the 2001 anthrax attack. The use of biological warfare can be traced back to 1346 A.D. when plaque afflicted human corpses were hurled over the besieged walls of Caffa. Presently, the use of biological warfare is banned following a United Nations convention signed in 1972. However, the absence of verification protocol has not been sufficient to prevent countries from developing biological warfare. Biological warfare has also become the weapons of choice for terrorist organizations. To combat this, the development of biodefense is an active research field.
Request a PDF Brochure with Report Analysis: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=5369
The research report analyzes the global biodefense market on the basis of market forces, current market trends, and major geographies. The report is an in-depth analysis of industry growth drivers, challenges, and opportunities of the market for the forecast period. It includes an analysis of recent technological developments in the market.
Using standard analytical tools such as SWOT analysis, the report presents the strengths, weakness, opportunities, and threats of the market until the end of the forecast period in 2023. The report also covers an analysis impact of macro and micro factors on the growth of the market, which is essential for existing market players as well as new entities that are interested in participating in the market. Thus, the report analysis helps in formulating informed business decisions by receiving detailed insights into the development of the key market segments.
The global biodefense market is displaying admirable growth due to the increasing importance for disease surveillance mission to combat bioterrorism. The outbreak of anthrax subsequent to September 11, 2001, attack has raised vigilance among government bodies for improving public health preparedness and to improve the response time in the event of a disaster.
The funding for preparedness of bioterrorism has augmented the capabilities of Public Health Services to enhance its surveillance activities, resulting in effective monitoring of community health. The increasing focus of Public Health Services for the development of tests and procedures to identify biothreat agents is also driving the biodefense market. The recent Ebola outbreak and nuclear crisis in Japan are anticipated to have a positive impact on the growth of the biodefense market.
The global biodefense market is divided into the regional segments of North America, Europe, Asia Pacific, and the Middle East and Latin America. North America is the largest market for biodefense due to enhanced lab capabilities and improved infrastructure for raising alarm for the threat to health. Europe is the second largest market for biodefense. Asia Pacific is expected to emerge as a significant market for biodefense due to the increasing adoption of precise analytical instruments and rapid advancement of the biotechnology industry. Other regions such as the Middle East and Latin America are anticipated to be significant regions for biodefense due to the expanding portfolio of leading biotechnology players in these regions.
Some of the leading companies operating in the global biodefense market are Alnylam Pharmaceuticals, Dynavax Technologies Inc., Emergent BioSolutions, SIGA Technologies, Acambis plc, Evogen Inc., Human Genome Sciences, and PharmAthene Inc.
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453